Current Phase II proprotein convertase subtilisin/kexin 9 inhibitor therapies for dyslipidemia (Q38124404)

29 August 2017

title

Current Phase II proprotein convertase subtilisin/kexin 9 inhibitor therapies for dyslipidemia (English)

1 reference

29 August 2017

1 reference

2

Robert A Hegele

0 references

author name string

Paul Lee

series ordinal

1

1 reference

29 August 2017

language of work or name

English

0 references

publication date

26 July 2013

1 reference

Expert Opinion on Investigational Drugs

29 August 2017

published in

1 reference

29 August 2017

volume

22

1 reference

29 August 2017

issue

11

1 reference

29 August 2017

page(s)

1411-1423

1 reference

European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.822485

2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.822485

Meta-analysis of comparison of effectiveness of lowering apolipoprotein B versus low-density lipoprotein cholesterol and nonhigh-density lipoprotein cholesterol for cardiovascular risk reduction in randomized trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.822485

Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.822485

Associations between apolipoprotein B, apolipoprotein AI, the apolipoprotein B/AI ratio and coronary heart disease: a literature-based meta-analysis of prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.822485

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.822485

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.822485

ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.822485

Use of Lipid-Lowering Medications and the Likelihood of Achieving Optimal LDL-Cholesterol Goals in Coronary Artery Disease Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.822485

Prevalence of dyslipidemia in statin-treated patients in Canada: Results of the DYSlipidemia International Study (DYSIS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.822485

Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.822485

Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.822485

Proportion and risk indicators of nonadherence to statin therapy: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.822485

Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.822485

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.822485

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.822485

Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.822485

HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.822485

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.822485

Effects of combination lipid therapy in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.822485

Effects of torcetrapib in patients at high risk for coronary events

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.822485

Effects of dalcetrapib in patients with a recent acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.822485

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.822485

Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.822485

Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.822485

HDL--is it too big to fail?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.822485

Monogenic hypocholesterolaemic lipid disorders and apolipoprotein B metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.822485

Microsomal triglyceride transfer protein inhibition-friend or foe?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.822485

Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.822485

Mipomersen, an antisense apolipoprotein B synthesis inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.822485

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.822485

The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.822485

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.822485

Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.822485

Sequence variations in PCSK9, low LDL, and protection against coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.822485

Longitudinal association of PCSK9 sequence variations with low-density lipoprotein cholesterol levels: the Coronary Artery Risk Development in Young Adults Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.822485

PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.822485

Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors in the treatment of hypercholesterolemia and other pathologies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.822485

NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.822485

Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.822485

PCSK9 plays a significant role in cholesterol homeostasis and lipid transport in intestinal epithelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.822485

Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.822485

Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.822485

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.822485

Anti-PCSK9 therapies for the treatment of hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.822485

The safety of therapeutic monoclonal antibodies: implications for cardiovascular disease and targeting the PCSK9 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.822485

The safety and side effects of monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.822485

Human antibodies from transgenic animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.822485

Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.822485

Clinical use of anti-TNF therapy and increased risk of infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.822485

Effect of a monoclonal antibody to PCSK9 on LDL cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.822485

Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.822485

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.822485

Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 In

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.822485

The relationship of molecular genetic to clinical diagnosis of familial hypercholesterolemia in a Danish population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.822485

Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.822485

Approach to lipoprotein management in 2001 National Cholesterol Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.822485

Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised con

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.822485

Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.822485

The evidence-base for the efficacy of lipoprotein apheresis in combating cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.822485

Efficacy of statins in familial hypercholesterolaemia: a long term cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.822485

Adherence to biologic DMARD therapies in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.822485

10.1517/13543784.2013.822485

21 January 2018

Identifiers

DOI

1 reference

29 August 2017

1 reference